与格雷夫病相关的多巴胺基系统功能障碍及其对条状皮质功能连接和认知功能的影响
Muhammad Abdullah1, Shih-Hsien Lin2, Li-Chung Huang3
1Department of Psychiatry, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Journal of the Formosan Medical Association = Taiwan yi zhi
|October 18, 2025
概括
格雷夫斯病 (GD) 患者表现出较低的多巴胺转运体 (DAT) 可用性和大脑连接性的改变,影响认知功能. 这些条状多巴胺系统的变化可能解释了GD的认知缺陷.
科学领域:
- 神经科学是一个神经科学.
- 放射学 放射学是一门学科.
- 精神病学是一个精神病学.
背景情况:
- 精神疾病中的认知缺陷往往与条形多巴胺基基调的降低和条形皮质功能连接 (FC) 的受损有关.
- 格雷夫斯病 (GD) 是一种甲状腺功能障碍,与条状腺多巴胺基基调的降低有关,可能导致认知障碍.
- 这项研究探讨了GD患者的条状多巴胺载体 (DAT) 可用性,条状皮质FC和认知功能 (IQ) 之间的关系.
研究的目的:
- 为了调查在格雷夫斯病 (GD) 患者的条状多巴胺载体 (DAT) 的可用性.
- 检查DAT可用性对纹状皮层功能连接 (FC) 的影响.
- 评估GD中DAT可用性,FC和全球认知功能 (IQ) 之间的关系.
主要方法:
- 招募了34名GD患者和24名健康对照 (HC).
- 使用单光子发射断层扫描 (SPET) 测量了DAT可用性.
- 使用静止状态功能性MRI (rs-fMRI) 和全尺度智商 (FIQ) 评估功能连接 (FC).
主要成果:
- 与HC相比,GD患者的左和右条纹DAT可用性显著降低.
- 较低的DAT可用性与条状区域和皮质区域之间改变的FC有很强的关联,包括insula和 parietal gyrus.
- 在GD患者中显著较低的全尺度智商 (FIQ) 评分与特定的前额-双肩和前额-三肩通路中中断的FC存在弱相关性.
结论:
- 格雷夫斯病的认知缺陷可能源于功能障碍的条状多巴胺基系统和改变的条状皮质FC.
- 与多巴胺功能相关的围-状连接受损,似乎在GD患者的智商下降方面发挥了作用.
- 这些发现凸显了多巴胺系统和相关大脑网络在GD背景下的认知功能中的重要性.
相关概念视频
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.2K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.2K
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:15Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
01:29Drugs Affecting Neurotransmitter Synthesis
2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K
01:24Parkinson's Disease: Treatment
972
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
972
01:22Alzheimer's Disease: Treatment
811
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
811